康泰医学(300869) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was CNY 130,053,431.63, a decrease of 36.37% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 58,830,005.54, down 31.28% year-on-year[5] - Basic earnings per share for Q3 2022 was CNY 0.1464, a decline of 31.29% compared to the previous year[5] - The company reported a 39.53% decline in net profit attributable to shareholders for the year-to-date, totaling CNY 174,206,387.64[5] - Total operating revenue for the current period was ¥462,183,267.50, a decrease of 35.7% compared to ¥719,299,418.51 in the previous period[18] - Net profit for the current period was ¥174,206,387.64, down 39.5% from ¥288,073,558.46 in the previous period[19] - Earnings per share (EPS) decreased to 0.4336 from 0.7170, representing a decline of 39.5%[19] - The company reported a total comprehensive income of ¥177,944,701.53, down from ¥287,990,743.62, a decrease of 38.3%[19] Assets and Liabilities - Total assets as of September 30, 2022, reached CNY 3,582,814,050.10, an increase of 28.46% from the end of the previous year[5] - The company's total assets as of September 30, 2022, amount to RMB 3,582,814,050.10, an increase from RMB 2,789,042,837.15 at the beginning of the year[14] - The company's total liabilities as of September 30, 2022, are RMB 1,643,481,979.88, compared to RMB 968,988,361.04 at the beginning of the year[14] - Total liabilities amounted to ¥1,643,481,979.88, up from ¥968,988,361.04, indicating a growth of 69.6%[16] - Total equity attributable to shareholders increased to ¥1,939,332,070.22 from ¥1,820,054,476.11, reflecting a growth of 6.5%[16] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 67,069,817.19, a significant increase of 419.05%[5] - Cash flow from operating activities generated ¥67,069,817.19, a significant increase compared to ¥12,921,766.30 in the previous period[20] - The cash flow from investing activities resulted in a net outflow of ¥58,506,008.22, an improvement from a net outflow of ¥82,081,793.67 in the previous period[20] - The net cash flow from financing activities was approximately ¥794.91 million, compared to a negative net cash flow of ¥21.45 million in the previous period[21] - The total cash and cash equivalents at the end of the period reached ¥1.41 billion, an increase from ¥711.19 million at the end of the previous period[21] - The cash inflow from financing activities totaled approximately ¥1.68 billion, significantly higher than ¥837.65 million in the previous period[21] - Cash outflow for financing activities was approximately ¥882.55 million, compared to ¥859.09 million in the previous period[21] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥11.71 million, contrasting with a negative impact of ¥11.33 million in the previous period[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,621[10] - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares[10] - The company has no preferred shareholders as of the reporting period[10] Research and Development - Research and development expenses for the year-to-date were CNY 66,072,763.60, an increase of 46.12% compared to the same period last year[8] - Research and development expenses increased to ¥66,072,763.60 from ¥45,218,587.41, marking a rise of 46.1%[18] Inventory and Financing Activities - The company experienced a 90.98% decrease in cash paid for other financing activities, reflecting reduced cash used for pledged time deposits[9] - The company's inventory as of September 30, 2022, is RMB 470,620,021.65, up from RMB 418,692,933.45 at the beginning of the year[14] - The company reported a short-term loan of RMB 848,459,974.94 as of September 30, 2022, compared to RMB 800,394,398.44 at the beginning of the year[14] - The company issued 7,000,000 convertible bonds with a total fundraising amount of RMB 700,000,000, which were listed on July 20, 2022[12] - The company issued convertible bonds, raising CNY 700 million, contributing to a 126.68% increase in cash and cash equivalents[8] - Sales of goods and services received cash of CNY 489,260,746.50, a decrease of 35.26% year-on-year[9]